Newcells Biotech

Newcastle Upon Tyne, United Kingdom Founded: 2014 • Age: 12 yrs
Induced pluripotent stem cell-derived organoid models are developed for research.

About Newcells Biotech

Newcells Biotech is a Healthcare company based in Newcastle Upon Tyne (United Kingdom) founded in 2014. Induced pluripotent stem cell-derived organoid models are developed for research. Newcells Biotech has raised $14.43 million across 9 funding rounds from investors including Mercia, European Union and NVM Private Equity. Newcells Biotech offers products and services including Retinal Organoids, Kidney Nephron Models, and Lung Airway Models. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is NEWCELLS BIOTECH LIMITED.

Company details

Newcells Biotech was founded in 2014 in Newcastle Upon Tyne, United Kingdom, within the biotechnology sector. Induced pluripotent stem cell-derived organoid models are created for research applications. Off-the-shelf products, such as neural progenitor cells and cardiomyocytes, are offered alongside custom reprogramming and differentiation services. These are provided to biopharmaceutical companies and research institutions to support drug development and scientific studies.

  • Headquarters Newcastle Upon Tyne, United Kingdom
  • Sectors
    Healthcare
  • Website newcellsbiotech.co.uk
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Newcells Biotech Limited
  • Date of Incorporation 15 Jan, 2015
  • Jurisdiction NEWCASTLE UPON TYNE, TYNE AND WEAR, UNITED KINGDOM
Key Metrics
  • Total Equity Funding
    $14.43M (USD)

    in 9 rounds

  • Latest Funding Round
    $1.47M (USD), Series B

    Dec 2024

  • Investors
    Mercia

    & 5 more

Products & Services of Newcells Biotech

Newcells Biotech offers a comprehensive portfolio of products and services, including Retinal Organoids, Kidney Nephron Models, and Lung Airway Models.

Retinal Organoids
In Vitro Model

Models for retinopathies and safety studies in drug testing

Kidney Nephron Models
In Vitro Model

Used for toxicity and drug interaction assessments

Lung Airway Models
In Vitro Model

Facilitates fibrotic disease and compound efficacy studies

Apps and channels of Newcells Biotech

its YouTube channel Newcells Biotech has 285 subscribers and 30 videos.

Newcells Biotech
YouTube 285 subscribers 30 videos Science & Technology
Open channel

Videos from Newcells Biotech

The most watched videos on Newcells Biotech's YouTube channel, Newcells Biotech (285 subscribers). Click a video to play it here.

Meet Dr Kathryn Garner - Former Head of Kidney Development
6K views
Our Lung Model Capabilities - Newcells Biotech
1.8K views
Meet Dr Valeria Chichagova - Associate Director of iPSC Technology & Head of Retina
1.6K views
Meet Dr Megan Webster - Former Head of Lung Development
1.3K views

More on Newcells Biotech.

Funding Insights of Newcells Biotech

Newcells Biotech has successfully raised a total of $14.43M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $1.47 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $14.43M
  • Total Rounds 9
  • Last Round Series B β€” $1.47M
  • Investors Count 6

All 9 funding rounds of Newcells Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2024$1.47MSeries B––
Feb 2024$2.95MSeries B–North East Fund
Feb 2021$7.37MSeries B–Mercia, Northstar Ventures
–
Jan 2020$357,134Grant––
Oct 2018$362,460Grant––
Jul 2018$2.63MSeries A––
Jan 2018$362,460Grant––
Jan 2017$287,660Grant––
Sep 2015Seed––
Valuation history

6 investors in total: 6 institutional.

Investors in Newcells Biotech

Newcells Biotech has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia, European Union and NVM Private Equity.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Early-stage investments are made in UK companies across diverse sectors.
northstarventures.co.ukNewcastle Upon Tyne, United Kingdom
Investment finance is provided to small and medium-sized enterprises.
northeastfund.orgNewcastle upon Tyne, United Kingdom
Regional investment funds are managed by North East Finance.
northeastfinance.orgGateshead, United Kingdom
Private equity investments are managed across the UK.
1984nvm.co.ukNewcastle Upon Tyne, United Kingdom
Investment management services are provided by Mercia to various clients.
1982mercia.co.uk
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Premium access

Investor details for Newcells Biotech

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Newcells Biotech

10 people are tracked at Newcells Biotech (8 in leadership, 1 in board & advisors, 1 in team).

NameRoleGroup
Colin Brown
Chief Scientific OfficerLeadership
Mike Nicholds
CEOLeadership
Simon Berry
Finance DirectorLeadership
Carolina Gándara
Principal Scientist, Head Of Retina Assay DevelopmentLeadership
Lyle Armstrong
Chief Scientific OfficerLeadership
Valeria Chichagova
Associate Director of iPSC Technology & Head of RetinaLeadership
John Burgess
Product Management & Marketing DirectorLeadership
Emile Shaffu
Global Sales DirectorLeadership
Peter Dines
Non-Executive DirectorBoard & advisors
James Cartwright
Marketing & Content ExecutiveTeam
Premium access

Complete people profiles for Newcells Biotech

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Newcells Biotech

3 dated milestones of Newcells Biotech across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Newcells Biotech is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series B, of $1.5M.

Web traffic of Newcells Biotech

The website of Newcells Biotech (newcellsbiotech.co.uk) receives about 5.2K visits a month.

  • Monthly visits
    5.2K

    ▲ 56.1% vs previous month

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Newcells Biotech (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Nanopore-based electronic systems for single-molecule analysis are developed.
2005Oxford, Oxfordshire, United KingdomUSD 1.34 BUSD 301.49 M1,372
Genetically modified cell lines are developed using AAV gene-editing platform.
2007Cambridge, Cambridgeshire, United KingdomUSD 46.29 M
Biological reagents and antibodies are developed for life science research.
1998Cambridge, Cambridgeshire, United KingdomUSD 78.8 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Newcells Biotech

Premium access

Complete news archive for Newcells Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Newcells Biotech

Newcells Biotech was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Newcells Biotech is headquartered in Newcastle Upon Tyne, United Kingdom.

Newcells Biotech is a funded company, having raised a total of $14.43M across 9 funding rounds to date.

Newcells Biotech was founded in 2014 in Newcastle Upon Tyne, United Kingdom, within the biotechnology sector. Induced pluripotent stem cell-derived organoid models are created for research applications. Off-the-shelf products, such as neural progenitor cells and cardiomyocytes, are offered alongside custom reprogramming and differentiation services. These are provided to biopharmaceutical companies and research institutions to support drug development and scientific studies.

Newcells Biotech offers Retinal Organoids, Kidney Nephron Models, and Lung Airway Models.

Newcells Biotech has 6 investors. Key investors include Mercia, European Union, NVM Private Equity, Northstar Ventures, and North East Fund.

Newcells Biotech operates through Newcells Biotech Limited.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available